García ZT, Villalobos SJA, Rodríguez HH

Language: Spanish
References: 15
Page: 299-309
PDF size: 409.55 Kb.

ABSTRACT

Myasthenia Gravis (miastenia gravis) is an antibody disorder of the neuromuscular junction involving the production of auto antibodies directed against the skeletal muscle receptors, most of them of acetylcholine (acetilcolinaR). It’s a relatively uncommon disease, although prevalence has increased over time, probably due to improved diagnosis of the disease and the increasing longevity of the population in general. The clinical hallmark is the fluctuating muscular weakness that increasing with effort. The ocular weakness is the most common initial presentation; it can remain confined to the ocular muscles or progress to the generalized weakness. The diagnostic can be supported in pharmacological tests (edrophonium test), immunological (acetylcholine receptor antibodies, muscle specific kinase antibodies, antistriational antibodies) or in electrophysiologic testing. The miastenia gravis treatment can be divided in: 1) sintomatic, including cholinesterase inhibitors, 2) short-term therapies (plasma exchange, intravenous immunoglobulin), y 3) long-term therapies (prednisone, azathioprine, mycophenolate mofetil, ciclosporin, tracolimus, cyclophosphamide, rituximab). At this time, the only absolute indication for thymectomy in the presence of thymoma. In the present work we present a myasthenia gravis case with a good treatment response and a literature revision.

REFERENCES

1. Tormoehlen LM, Pascuzzi RM. Thymoma, Myasthenia Gravis, and Other Paraneoplastic Syndromes. Hematol Oncol Clin N Am 2008;22:509-526.

2. Merggioli M, Sanders D. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 2009;8:475-490.

3. Deymeer F, Gungor-Tuncer O, Yilmaz V, Parman Y, Serdaroglu P et al. Clinical comparison of anti-MuSK- vs anti-acetilcolinaRpositive and seronegative myasthenia gravis. Neurology 2007; 68:609-611.

4. Skeie G, Apostolski S, Evoli A, Gilhus N, Hart L et al. Guidelines for the treatment of autoimmune neuromuscular trasmission disorders. European Journal of Neurology 2006;13:691-699.

5. Schiavi A, Papangelou A, Mirski M. Preoperative Preparation of the Surgical Patient with Neurologic Disease. Med Clin N Am 2009;93:1123-1130.

6. Sener M, Bilen A, Bozdogan N, Kilic D, Arslan G. Laryngeal Mask Airway insertion with total intravenous anesthesia for trassternal thymectomy in patients with myasthenia gravis: report of 5 cases. Journal of Clinical Anesthesia 2008; 20:206-209.

7. Brodsky M, Smith J. Exacerbation of myasthenia gravis after tourniquet release. Journal of Clinical Anesthesia 2007; 19:543-545.

8. Brambrink A, Kirsch J. Perioperative Care of Patients with Neuromuscular Disease and Dysfunction. Anesthesiology Clin 2007; 25:483-509.

9. Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis. A randomized controlled trial. Neurology 2007; 68:837-841.

10. Sanders D. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008;71:394-399.

11. Cavalcante P, Barberis M, Cannone M, Baggi F, Antozzi C. Detection of poliovirus-infected macrophages in thymus of patients with myasthenia gravis. Neurology 2010;74:118-1126.

12. Matsui N, Nakane S, Saito F, Ohigashi I, Nakagawa Y et al. Undiminished regulatory T cells in the thymus of patients with myasthenia gravis. Neurology 2010;74:816-820.

13. Alshekhlee A, Miles J, Katirji B, Preston D, Kaminski H. Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology 2009;72:1548-1554.

14. Burns T, Conaway M, Sanders D. The miastenia gravis Composite. A valid and reliable outcome measure for myasthenia gravis. Neurology 2010;74:1434-1440.

15. Sanders D, Hart I, Mantegazza R, Shukla S, Siddiqui Z. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 2008;71:40-406.